ARTICLE | Company News
3SBio gets worldwide rights to Apexigen's anti-TNF
June 23, 2015 1:38 AM UTC
3SBio Inc. (HKSE:1530) received ex-China rights to SSS07 from Apexigen Inc. (San Carlos, Calif.). 3SBio already held rights in China to the humanized mAb that inhibits tumor necrosis factor (TNF) alpha. Neither company would disclose terms of the deal.
In March, 3SBio began a dose-escalating Phase I study of SSS07 to treat rheumatoid arthritis and other inflammatory diseases. It expects to begin a multiple-dose Phase Ib study of the candidate in early 2016. ...